The Hudson study (NCT03334617) was the first to explore the efficacy of the CD73 monoclonal antibody oleclumab in combination with durvalumab in patients with metastatic NSCLC following failure of PD-1/PD-L1 maintenance therapy (66). The gene discussed is CD274; the disease is non-small cell lung carcinoma.